Governance Arbutus Biopharma Corporation

ABUS

CA03879J1003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
4.530 ^USD	-3.62%		-2.79%	-5.82%

Mar. 04	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
Mar. 04	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT

Executive Committee: Arbutus Biopharma Corporation

Manager

Positions heldSince

Lindsay Androski

49 year

Chief Executive Officer	2025-02-23
President	2025-02-23

Tuan Nguyen

50 year

Director of Finance/CFO

2025-03-27

Composition of the Board of Directors: Arbutus Biopharma Corporation

Director

CommitteesSince

Lindsay Androski

49 year

Chairman

2025-02-23

Roger Sawhney

56 year

Audit Committee	2025-08-03
Compensation Committee	2024-08-13
Governance Committee	2025-08-03
Nominating Committee	2025-08-03

Matthew Gline

41 year

Compensation Committee	2025-02-23
HR Committee	2025-02-23
Governance Committee Chair	2025-02-23
Nominating Committee Chair	2025-02-23

Robert Beardsley

65 year

Audit Committee	2025-02-24
Compensation Committee Chair	2025-02-24
HR Committee Chair	2025-02-24

Latest Appointments: Arbutus Biopharma Corporation

Dec. 05	Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026	CI
Dec. 04	Trevi Therapeutics Names David Hastings CFO	MT
25-08-06	Arbutus Biopharma Corporation Announces Board Changes	CI
25-08-06	Arbutus Biopharma Corporation Announces Appointment of Dr. Harry Janssen to Scientific Advisory Board	CI
25-06-25	Arbutus Launches a New Scientific Advisory Board	CI
25-03-27	Arbutus Biopharma Corporation Announces Executive Changes	CI
25-02-25	Roivant Sciences Announces Resignation and Replacement of Directors at Arbutus Biopharma	CI

More news

Former Officers and Directors: Arbutus Biopharma Corporation

Insider

Positions held

SinceUntil

David Hastings

Comptroller/Controller/Auditor	2019-03-30	2025-03-27
Director of Finance/CFO	2018-06-10	2025-03-27

Richard Henriques

Director/Board Member	2014-11-30	2025-02-23
Independent Dir/Board Member	2014-11-30	2025-02-23

Frank Torti

Chairman	2018-11-25	2025-02-23
Independent Dir/Board Member	2018-11-25	2025-02-23

James Meyers

Director/Board Member	2018-10-22	2025-02-23
Independent Dir/Board Member	2018-10-22	2025-02-23

Keith Manchester

Director/Board Member	2015-03-03	2025-02-23
Independent Dir/Board Member	2015-03-03	2025-02-23

Daniel Burgess

Director/Board Member	2017-03-22	2025-02-23
Independent Dir/Board Member	2017-03-22	2025-02-23

Michael Sofia

Chief Tech/Sci/R&D Officer

2015-02-28

2024-12-30

William Collier

Director/Board Member	2019-06-23	2023-12-30
Chief Executive Officer	2019-06-23	2023-12-30
Investor Relations Contact	2019-06-23	2021-09-20
Public Communications Contact	2019-06-23	-
President	2019-06-23	2023-12-30

Elizabeth Howard

Compliance Officer	2016-03-07	2023-07-09
General Counsel	2016-03-07	2023-07-09
Corporate Secretary	-	2023-07-09

Gaston Picchio

Corporate Officer/Principal

2018-10-08

2022-12-30

Myrtle Potter

Director/Board Member	2018-10-17	2020-02-17
Independent Dir/Board Member	2018-10-17	2020-02-17

Mark J. Murray

Director/Board Member	2011-10-13	2019-06-23
Chief Executive Officer	2008-05-29	2019-06-23
President	2008-05-29	2019-06-23

Koert VandenEnden

Comptroller/Controller/Auditor	2018-02-15	2019-03-30
Director of Finance/CFO	2018-02-15	2018-06-10
Corporate Officer/Principal	2016-09-30	2018-02-12

Vivek Ramaswamy

Director/Board Member	2015-03-03	-
Chairman	-	2018-11-25
Independent Dir/Board Member	2015-03-03	2018-11-25

William T. Symonds

Director/Board Member	2014-03-03	2018-10-21
Corporate Officer/Principal	2014-03-03	2018-10-21

Tiffany Tolmie

Investor Relations Contact

2018-05-31

Peter Lutwyche

Chief Tech/Sci/R&D Officer	2014-12-31	2018-04-10
Corporate Officer/Principal	2008-05-29	-

James Heyes

Corporate Officer/Principal

2015-07-31

2018-03-31

Bruce Cousins

Director of Finance/CFO	2013-10-06	2018-02-12
Investor Relations Contact	-	2018-02-12

Frank Karbe

Director/Board Member	2010-01-27	2017-12-31
Independent Dir/Board Member	2011-10-16	2017-12-31

Adam Cutler

Corporate Officer/Principal

2015-03-17

2017-10-31

Helia Baradarani

Investor Relations Contact

2017-01-31

Michael Jeffrey Abrams

Director/Board Member	2009-09-01	2014-06-15
Independent Dir/Board Member	2011-10-16	2014-06-15
Corporate Officer/Principal	-	2016-09-29

Mark Kowalski

Chief Tech/Sci/R&D Officer

2013-08-11

2016-09-29

Patrick T. Higgins

Chief Operating Officer

2016-04-29

Paul Brennan

Corporate Officer/Principal

2010-09-08

2015-07-31

Donald Jewell

Director/Board Member	2009-09-01	2015-03-03
Independent Dir/Board Member	2011-10-16	2015-03-03

Peggy Phillips

Director/Board Member	2014-02-11	2015-03-03
Independent Dir/Board Member	2014-02-11	2015-03-03

Diane Gardiner

Human Resources Officer

2013-02-28

2015-02-28

Dan Kisner

Chairman	2010-01-27	2015-02-28
Independent Dir/Board Member	2010-01-27	2015-02-28

Ian MacLachlan

Chief Tech/Sci/R&D Officer

2008-05-29

2014-12-30

Ken Galbraith

Director/Board Member	2010-01-27	2014-08-21
Independent Dir/Board Member	2010-01-27	2014-08-21

Jodi Regts

Investor Relations Contact

2010-12-31

2013-12-31

Ian Mortimer

Director of Finance/CFO

2003-12-31

2013-09-30

Arthur M. Bruskin

Director/Board Member	2008-04-30	2012-05-31
Independent Dir/Board Member	2011-10-16	2012-05-31

Ronald Ian Lennox

Director/Board Member	2009-09-01	2012-05-31
Independent Dir/Board Member	2011-10-16	2012-05-31

James W. Hudson

Director/Board Member

2007-04-29

2010-06-22

Gary Frashier

Director/Board Member

2007-04-29

2010-06-22

R. MacKay-Dunn

Corporate Secretary

2011-10-16

K. Michael Forrest

Chairman

2007-04-29

2010-01-27

Timothy M. Ruane

Director/Board Member	2005-11-30	2008-05-29
Chief Executive Officer	2005-11-30	2008-05-29
President	2005-11-30	2008-05-29

Sheldon D. Reid

President

2007-11-08

Pieter Cullis

Director/Board Member

2007-04-29

Darrell J. Elliott

Director/Board Member

2007-04-29

David Main

Chief Executive Officer	1999-06-30	2005-05-31
Corporate Officer/Principal	1996-08-31	1999-06-30
President	1999-06-30	2005-05-31

Alexandra Mancini

General Counsel

2000-12-31

2005-05-31

Shelley McCloskey

Chief Tech/Sci/R&D Officer	1999-12-31	2004-12-31
Human Resources Officer	1999-12-31	2004-12-31

Jim J. Miller

Chairman

1991-12-31

Rene Cornelis Rijnbrand

Corporate Officer/Principal

Julie P. Rezler

Investor Relations Contact

Gregg Ashby

Public Communications Contact

Herbert Conrad

Director/Board Member	-	-
Independent Dir/Board Member	-	-

Bruce V. Dorsey

Corporate Officer/Principal

Frank Davis

Director/Board Member

Thomas MacRury

Corporate Officer/Principal

Jian Xin Chen

Corporate Officer/Principal

Tammy Mullarky

Corporate Officer/Principal

John J. Swift

Director/Board Member

Marcia MacDonald

Corporate Officer/Principal

Paul King

Corporate Officer/Principal

Mona Newkirk

Corporate Officer/Principal

Barry Gordon

Director/Board Member

Jeffrey Charpentier

Director of Finance/CFO

Age distribution of managers

Parity Men Women

Male	4
Female	1

Of which Executive Committee

Male	1
Female	1

Of which Directors

Male	3
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patientsâ€™ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

Employees

Sector

Biotechnology & Medical Research

More about the company